Harmonic Discovery (Medium) · Aug 2024
Company blog post discussing data challenges and the case for explainable, data-rich AI in drug discovery; written by Anna Cichońska and Rayees Rahman.
Multi-targeted therapeutics to treat complex diseases
Public company, workplace, funding, and market signals
Harmonic Discovery is a New York-based precision pharmacology biotech using machine learning, structural bioinformatics, and generative chemistry to design multi-target kinase therapeutics and partner on drug discovery and licensing programs.
Primary product
An experimentally validated precision pharmacology platform for kinase drug discovery, including its generative chemistry and selectivity tools (Banyan, Kanopy, Terra) and lead preclinical program HD-10019.
Founded
2021
Headquarters
JLABS@NYC, New York City, New York, United States
Team size
1-10
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Precision pharmacology / kinase drug discovery
Offices
6 jobs at Harmonic Discovery
Business model
Stage
seed
Total raised
$8.1M
Latest round
Incubator/Accelerator - IV · Sep 2025
Leadership
Founder & Chief Executive Officer
Founder & Chief Scientific Officer
Director of Data Science and Head of European Operations
Director of Chemical Informatics
Founders
Jason Lee
Co-founder & COO
Interdisciplinary, science-driven, and collaborative; the company describes its team as passionate innovators, radical thinkers, and collaborative builders, with a remote-first US work setup and regular company off-sites.
Work style
Remote
Compensation
Publicly advertised compensation is competitive salary plus equity, a 401(k) match up to 4%, and a five-week PTO package with a holiday bonus; no public salary bands were found.
Benefits
Pricing
Custom collaboration/licensing agreements; no public pricing published.
Differentiators
Technology
Customers
Competitors
Estimated revenue
under $1M
Estimated monthly visits
825
Harmonic Discovery (Medium) · Aug 2024
Company blog post discussing data challenges and the case for explainable, data-rich AI in drug discovery; written by Anna Cichońska and Rayees Rahman.
Business Wire · Apr 2024
Harmonic Discovery announced a collaboration with Turbine to co-develop a novel cancer therapy using simulation-guided biology and its multi-target kinase chemistry platform.
PR Newswire · Jan 2024
Harmonic Discovery announced an exclusive licensing agreement for HD-10019, a novel small-molecule candidate for FLT3-mutated AML, and said preclinical development was underway.
Harmonic Discovery (Medium) · Sep 2022
Company launch post announcing $8 million seed funding led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital, and select angel investors.
Harmonic Discovery (Medium) · Sep 2022
Founding post describing the mission to embed disease complexity into drug discovery and build a machine-learning-first platform for kinase therapeutics.